Teva Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	17,349	17,258	16,544	15,846	14,925	15,878
Revenue Growth (YoY)	4.41%	4.32%	4.41%	6.17%	-6.00%	-4.69%
Cost of Revenue	8,317	8,320	8,481	8,200	7,952	8,284
Gross Profit	9,034	8,938	8,064	7,645	6,973	7,594
Selling, General & Admin	3,356	3,973	3,702	3,498	3,445	3,528
Research & Development	989	1,013	998	953	838	967
Other Operating Expenses	1,700	1,776	3,680	2,811	4,994	1,384
Total Operating Expenses	6,045	6,762	8,380	7,262	9,277	5,879
Operating Income	2,989	2,176	-316	383	-2,304	1,715
Total Non-Operating Income (Expense)	-927	-952	-967	-1,008	-859	-1,058
Pretax Income	1,366	1,223	-1,284	-624	-3,163	658
Provision for Income Taxes	-186	-180	676	-7	-643	211
Net Income	1,552	1,403	-1,960	-617	-2,520	447
Minority Interest in Earnings	16	22	-319	-54	-32	48
Net Income to Common	1,564	1,410	-1,639	-559	-2,446	417
Shares Outstanding (Basic)	1,150	1,145	1,131	1,119	1,110	1,102
Shares Outstanding (Diluted)	1,169	1,163	1,131	1,119	1,110	1,107
Shares Change (YoY)	2.61%	2.83%	1.07%	0.81%	0.27%	1.10%
EPS (Basic)	1.37	1.23	-1.45	-0.50	-2.20	0.38
EPS (Diluted)	1.33	1.21	-1.45	-0.50	-2.20	0.38
Free Cash Flow	1,172	1,148	749	842	1,042	236
Free Cash Flow Growth	2.09%	53.27%	-11.04%	-19.19%	341.52%	-63.01%
Free Cash Flow Per Share	1.00	0.99	0.66	0.75	0.94	0.21
Gross Margin	52.07%	51.79%	48.74%	48.25%	46.72%	47.83%
Operating Margin	17.23%	12.61%	-1.91%	2.42%	-15.44%	10.80%
Profit Margin	8.95%	8.13%	-11.85%	-3.89%	-16.88%	2.82%
FCF Margin	6.76%	6.65%	4.53%	5.31%	6.98%	1.49%
EBITDA	3,988	3,178	743	1,536	-996	3,045
EBITDA Margin	22.99%	18.41%	4.49%	9.69%	-6.67%	19.18%
EBIT	2,989	2,176	-316	383	-2,304	1,715
EBIT Margin	17.23%	12.61%	-1.91%	2.42%	-15.44%	10.80%
Effective Tax Rate	-13.62%	-14.72%	-52.65%	1.12%	20.33%	32.07%

SEC Filings: 10-K · 10-Q